Subject:
- Active Substance: Selumetinib
- Name: Koselugo®
- Therapeutic area: Neurofibromatosis
- Pharmaceutical company: AstraZeneca GmbH
Time table:
- Start: 15.08.2021
- Final decision by G-BA: 03.2022
- This decision remains valid until: 01.07.2023
Final decision:
- Hint for a non-quantifiable additional benefit (orphan drug)